" class="no-js "lang="en-US"> Gliknik - Medtech Alert
Monday, October 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Gliknik | Pharmtech Focus

Gliknik

About Gliknik

Gliknik

Related Story

Fundraising

 Gliknik Inc. Raises $11.5 Million in Series C Financing | Pharmtech Focus

Gliknik Inc. Raises $11.5 Million in Series C Financing

June 25 2021

Gliknik Inc., an immunology company dedicated to patients with cancer and autoimmune disorders, today announced […]